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Executive summary 
 
The pharmaceutical sector is one of the thrust sectors in Bangladesh. Due to recent development of this 
sector, the industry is exporting medicines to global markets, including the European market. This sector 
is also providing 97% of the total medicine requirement of the local market. Leading companies are 
expanding their business with the aim to expand into the export market. 
GlaxoSmithKline (GSK) is a leading multinational healthcare company operating in Bangladesh for 
years. GSK aims at offering high quality medicines and vaccines to enhance the quality of human life 
around the world. This study on “Inventory Management and the Financial Performance of the 
Pharmaceutical Segment of GlaxoSmithKline Bangladesh Limited” was aimed to identify the impact of 
pharma segment’s inventory management on the financial performance of GSK. 
In this report we can see the financial performance of pharmaceutical segment of GSK Bangladesh LTD 
and comparison among its competitors. In addition, necessary suggestions are also provided for 
improving its present market condition. It is found that it would be wise for GSK to concentrate on 
formulating and exercising competitive business strategies, such as addressing efficient inventory 
management procedure, to regain its market position. 
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Chapter one: Background of the report 
1.1 Introduction: 
The Pharmaceutical industry is the playing an important role in the economy of Bangladesh. It is known 
as the most developed hi-tech sectors within the country’s economy. After the promulgation of Drug 
control ordinance in 1982, the local Pharmaceutical companies of country get rapid support for growth 
and development of this sector was accelerated. There are now about 210 companies in this sector and the 
total market size is about taka 76,500 million per year. This industry is now self-sufficient in meeting the 
local demand. In addition, it is the second highest contributor to the national economy after garments, and 
it is the largest white-collar intensive employment sector of the country.   
GlaxoSmithKline plc (GSK) is a leading multinational; healthcare company operating in Bangladesh for 
years.  It concentrates on the development, manufacturing and commercialization of Pharmaceutical and 
consumer health related products.  
1.2 Purpose: 
The purpose of this report is to fulfill the requirement of internship completion in order to complete BBA 
program from the department of BRAC Business School, BRAC University.  
1.3 Objectives:  
The broad objective of this report is to identify the impact of pharmaceutical segment’s inventory 
management on the financial performance of GSK. To achieve this broad objective following specific 
objectives were set for conducting this study: 
A.  assess effectiveness of the inventory management 
B.  recognize the level of impact of the inventory management on the respective years’ financial 
performance 
C.  explore the nature of existing inventory management practice 
1.4 Significance of the study: 
Inventory is the key current asset with a substantial portion in the form of work in progress, spares, 
and consumables, which are not as liquid as cash and receivables. It has significant impact on 
manufacturing operations, cost of goods sold, sales, net income, return on assets, gross margin etc. 
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Organizations, specially manufacturing organizations, need to work on increasing its liquidity levels 
by streamlining its processes to ensure better and effective inventory management. Exploring the 
effect of inventory management practices and performance on financial and operational performance 
is valuable initiative for the practical understanding manufacturing and financial accounting, as well 
as management of manufacturing operations. GSK’s pharmaceutical segment, rendering a strong and 
disciplined operation, provides the opportunity to explore this inventory management and financial 
performance relationship, which might be considered to bring insight the operations practice by the 
manufacturing organizations, specially the pharmaceutical products manufacturers in Bangladesh. 
 
1.5 Limitations:  
Preparing a report, a major player of which is inventory accounting, requires huge amount of information 
and plant based working   experience.  The limitations are: 
I. Lack of opportunity to visit the plant to understand the inventory accounting comprehensively 
II. Complex financial management system (almost times information is handled partially by an 
employee) of GSK 
III. Lack of access to comprehensive industry information (competitor scenario) 
IV. Organizational compliance regarding information confidentiality organization. 
1.6 Methodology:  
This chapter describes the process in which the research was conducted right from selecting research 
problem, planning and designing the research, preparation of data collection tools and their purpose, 
identification of the sample area, selecting sample respondents, details of respondents and sampling 
strategy to be used and finally the procedure of collecting data. In accordance with the objective of the 
research, both qualitative and quantitative approaches were employed. 
Scope: 
The pharmaceutical segment of GSK was chosen due to limit the scope of the report as feasible as 
possible and the organized nature of information of this production segment. Considering the availability 
of information and the objectives of the study, recent three years’ annual report and inventory statement 
were chosen for the analysis, three employees of GSK, the respondents of the questionnaire, were chosen 
based on their experience and expertise regarding inventory, as well as financial management. 
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Approach of research: 
In according with the objective of the research, both qualitative and quantitative approaches were 
employed. This mixed method research considered the qualitative approach to explore the situation 
inventory management practice , and employed quantitative approach and techniques to analyze and 
interpret cause –effect relationship between inventory management and financial performance, where 
inventory management was considered as the independent variable.  
Data collection tools: 
A data requirement model was formulated to collect information regarding sales, inventory supply 
(including inventory segments information), inventory costs, lead- time etc to conduct the EOQ analysis 
to find out the comparative financial performance at pharmaceutical industry financial performance of 
Square Pharmaceutical Limited, Beximco Pharmaceutical Limited, and Renata Phannaceutical Limited 
were selected. Besides this quantitative tool, an interview schedule with close-ended items was designed 
to get a detail insight on this issue. 
Data collection Method: 
Data were collected from both primary and secondary sources; Primary data was collected by executing 
an inventory management schedule and Questionnaire.  
Secondary data:  Annual report and inventory statement of GSK and annual reports of three competing 
pharmaceutical organizations were reviewed as important secondary source of annual financial 
information. Moreover, GSK, Website remained as a useful source.  
. 
Data Analysis and Interpretation: 
To explore the inventory management scenario, profitability analysis, EOQ analysis and inventory 
turnover ratios were found appropriate. Monetary values of quarterly operations were used as inputs for 
these two quantitative analysis models. 
Simple mathematical tools (ex. percentage, ratio) were used to analyze and describe the individual and 
comparative financial performance. In order to identify the level of effect on inventory management on 
financial performance, where inventory management was considered as the independent variable and 
financial performance was considered as the dependent one. 
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Chapter Two: Literature Review 
This chapter analyzed the relevant literature on inventory management as studied by other scholars and it 
has been discussed in relation to the research objectives. This chapter deals with why firms hold 
inventory, inventory management definition and objectives, techniques to be used in inventory 
management, inventory models and systems and the costs to be associated with inventory management, 
inventory centre methods. 
2.1 Inventory 
Inventory is the working asset, held for eventual sale by a firm and is the stock of the product a company 
is manufacturing for sale and the components that make up a product. In general, inventory exists in three 
forms; raw materials, work in progress and finished goods. Raw materials are the basic inputs that are 
converted into finished goods through the manufacturing process. Work in progress is semi-finished 
products. They are the products that have been partially finished. Finished goods inventory refers to those 
units that are complete and ready for sale. It provides a link between production and consumption of 
goods. 
(KILAMA, ACAYE PHILIP, 2011) 
 
 
 
 
2.2 Inventory Management:  
Inventory management refers to the process of managing the stocks of finished products, semi-finished 
products, and raw materials by a firm. Inventory management, if done properly, can bring down costs and 
increase the revenue of a firm. 
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Ideal level of investment in inventory management depends on the volume and value of inventory as a 
percentage of the total assets of a firm. The importance of inventory management varies according to 
industries. For example, an automobile dealer has very high inventories, sometimes as high as 50 per cent 
of the total assets, whereas in the hotel industry it may be as low as 2 to 5 per cent. (KILAMA, ACAYE 
PHILIP, 2011) Inventory management process is a continuous arid complex one. ‘Specialized staffs are 
required to employ for efficient inventory management. For manufacturing organizations, this 
management process begins as soon as the production is started and raw materials are ordered. Inventory 
management systems are used to establish when to place orders and in what quantities, these management 
systems have an objective of minimizing investment in inventory without necessarily impairing 
production. The aim of inventory management is to manage and maintain uninterrupted supplies of 
inventories for ongoing operations at the minimum possible cost. 
Inventories constitute the most significant part of current assets of large number of firms. Management of 
inventory requires considerable amount of planning and funds. Transactions, precautionary and 
speculative motives influence firms to practice a Held inventory policy Kilma (2011) explains the 
transaction motive is aimed at facilitating smooth sales operations, while precautionary motive involves 
holding inventory to guard against unforeseen or unpredictable changes in demand and supply forces in 
the market, and speculative motive indicating holding either excess or shortages stocks to take advantage 
of price fluctuation. 
2.3 Economic order quantity (EOQ) 
Economic order quantity (EOQ) is the order quantity of inventory that minimizes the total cost of 
inventory management. Two most important categories of inventory costs are ordering costs and carrying 
costs. Ordering costs are costs that are incurred on obtaining additional inventories; they include costs 
incurred on communicating the order, transportation cost, etc. Carrying costs represent the costs incurred 
on holding inventory in hand. They include the opportunity cost of money held up in inventories, storage 
costs, spoilage costs, etc. Ordering costs and carrying costs are quite opposite to each other. If we need to 
minimize carrying costs we have to place small order which increases the ordering costs. If we want 
minimize our ordering costs we have to place few orders in a year and this requires placing large orders 
which in turn increases the total carrying costs for the period. We need to minimize the total inventory 
costs and EOQ model helps us just do that. An Economic order quantity (EOQ) could assist in deciding 
what would be the best optimal order quantity at the company’s lowest price. (Gonzalez, March 2010) 
Gonzalez, in this study indicated an analysis of Economic Order Quantity and Reorder Point Inventory 
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Control Model could resolve the forecasting issues and improve financial performance of a certain 
organization. 
Gonzalez described the fundamental theory of the Economic Order Quantity (EOQ) through this formula: 
                                                   )*/()**2( CHSDQ =  
Here,  
(EQ: 1) 
Q= the EOQ order quantity  
D= the annual demand of product in quantity per unit time 
S= the product order cost. This is the flat fee charged for making any order 
C= Unit cost 
H= Holding cost per unit as a fraction of product cost.  
Total inventory costs = Ordering costs + Holding costs 
In summary, the EOQ as, “Determining the order quantity “Q”, that balances the order cost “C” and the 
holding costs “H”, to minimize total costs. The greater the Q, the order cost would decrease due to less 
orders placed. On the other hand, if Q increases, the holding cost would increase due to higher inventory 
levels.” (Gonzalez, March, 2010) 
The Economic Order Quantity (EOQ) formula has been used in both engineering and business disciplines. 
(Roachl School of Business, 2005) Roach said, business disciplines study the EOQ in both operational 
and financial courses as EOQ formulas have practical and specific applications in illustrating concepts of 
cost tradeoffs; as well as specific application in inventory. In order to have suitable results for any 
inventory model, accurate product costs, activity costs, forecasts, history, and lead times need to be in 
place. (Beate Klingenberg, 2010). 
2.4 Inventory turnover ratio: 
Inventory turnover, ratio of a firm is cost of goods sold to its average inventory level, is commonly used 
to measure performance of inventory managers, compare inventory productivity across retailers, and 
assess performance improvements over time. 
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The following widely used financial rations employ inventory: 
2.4.1 Inventory to current asset 
Inventory to current asset= (inventory /current Assets)* 100 
This ratio gives the inventory as a percentage of the current assets and as such measures the percentage of 
current assets tied up in inventory. Since inventories are not self liquidating a high Inventory to Current 
Assets can indicate obsolete or defect inventory. Clearly, after introducing JIT this number should 
decrease significantly, theoretically to zero. Since there are costs associated with carrying inventory, this 
would indicate that these costs are reduced. 
2.4.2 Inventory turnover ratio 
Inventory turnover ratio (COGS/Average inventory) *100 
This ratio evaluates the operating efficiency concerning the usage of inventory in the production process. 
Sometimes net sales are used in the numerator. Regardless, since JIT theoretically reduces the 
denominator to zero, this ratio is no longer measurable. Hence, this phenomenon will indicate the correct 
implementation of JIT.  Finally, one can evaluate the difference between the Current and Quick Ratio: 
 
 2.4.3 Current ratio 
Current ratio = (Current assets/Current liabilities) 
2.4.4 Quick ratio 
Quick ratio = [(Current assets—Inventory)/current liabilities)] 
(Beate Klingenberg, 2010) 
Inventory as an asset on the balance sheet of companies has taken on increased importance because many 
companies are applying the strategy of reducing their investment in fixed assets like plants, warehouses, 
equipment and machinery, and so on, which even highlights the significance of reducing inventory. 
Changes in inventory levels affect Return on Assets (ROA), which is an important financial parameter 
both from internal and external perspectives. Reducing inventory usually improves ROA, and vice versa 
if inventory goes up without offsetting increases in revenue. (KILAMA, ACAYE PHILIP, 2011) 
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Kilma (2011) described, the relationship between Inventory management and the financial performance 
of an organization mainly manifests itself through the material requirements planning which is the system 
of planning, and scheduling the time- phased material requirements for production operations improved 
customer services and other advantages come at a cost however. They also require a realistic master 
production schedule to specie’ when various end items will be completed. Finally and perhaps most 
important, they require a certain discipline, then a commitment by schedules and employees to make the 
system work. Effective inventory planning ensures inventory reduction, reduction in production and 
delivery lead times, realistic commitments, and increased efficiency. 
Clodfelter in 2003 (KILAMA, ACAYB PHILIP, 2011) adds that a good inventory control system 
maintains a proper relationship between sales and inventory. Without inventory control procedures in 
place, the store or department can become overstocked or under stocked. Kilma (2011) established a high 
positive relationship between inventory management and financial performance. 
 
Chapter Three: Pharmaceutical Industry overview in Bangladesh: 
The pharmaceutical industry is worldwide reputed for its fastest growing industry. Bangladesh has 
sizeable Pharma industry with potential to reach the very best of the global standard. This industry is 
considered as the second largest contributor to the national revenue, as well as the second largest 
contributor to the government exchequer. In the past ten years, the Bangladesh pharmaceutical market has 
double in the growth, reaching a total value of US$929 million in from the fourth quarter of 2009 to third 
quarter of 2010. 
Currently, the Bangladesh pharmaceutical market is dominated by the ten local players. The local 
companies contribute 68% to the total market, while the top 20, just four of which are multinational, 
contribute 84%. Nearly 200 manufacturers are responsible for 8,000 branded generics now available to 
the local population. Competition is intense, but the branded generics nature of the market enables top 
companies to command premium prices and ensure a return on their investment (IMS Bangladesh, 2013) 
The Bangladesh pharma market is profoundly retail oriented, with the bulk of distribution undertaken by 
the companies themselves, leaving wholesalers to play a limited role. Patients must advocate for 
themselves within the system, as health insurance is virtually non- existent and patients are expected to 
pay full price for medicines.  
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Habib and Alam(2011) through their study tried to identify the existing problems and prospects in the 
pharmaceutical sector in Bangladesh. They concluded, adequate infrastructure and use of trained work 
force were two essential requisites for implementation of national pharmaceutical policies in Bangladesh. 
They also put light on the fact that the country was importing significant amount of medicine and raw 
materials for the industry from abroad. However, they added, industry has started to export its products in 
foreign market, especially in Middle East and Europe with great success. ( Alam, 2011) 
Chapter Four: History of GSK, Products of GSK and GlaxoSmithKline (GSK) Bangladesh Limited 
This report is fulfilled and supported by GlaxoSmithKline (GSK) Bangladesh Limited. It is a world’s 
leading research-based pharmaceutical company with a powerful combination of skills and resources that 
provides a platform for delivering strong growth in today’s rapidly changing healthcare environment. It is 
the only British organization in the world’s top 20 pharmaceutical companies. Subsidiary companies are 
established over 50 countries of the world many with their own manufacturing facilities and the group 
have agency representation in more than 100 offices. GSK has leadership in four major therapeutic areas- 
anti invectives, central nervous system (CNS) and respiratory & gastro- intestinal! Metabolic. In addition 
it is a leader in the important areas of vaccines and has growing portfolio of oncology products. GSK 
supplies products to 140 global markets and has over 100,000 employees worldwide.GSK has 180 
manufacturing site in 41 countries. Every second, this organization distributes more than 35 doses of 
vaccines. Every minute, more than 1100 prescriptions are written for GSK products.  
4.1 GlaxoSmithKline- At a Glance: 
 GSK’s mission is to improve the quality of human life by enabling people to do more, feel better 
and live longer 
 GSK is a research-based pharmaceutical company. 
 GSK is committed to tackling the three “priority’ diseases identified by the World Health 
Organization: HIV/AIDS, tuberculosis and malaria 
 GSK’s business employs around 99,000 people in over 100 countries 
 GSK makes almost four billion packs of medicines and healthcare products every year 
 In November 2009, GSK launched ViiV Healthcare, a global specialist HIV company established 
by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with 
HIV. 
 Many of their consumer brands are household names: Ribena, Horlicks, Lucozade, Aquafresh, 
Sensodyne, Panadol, Tums, and Zovirax 
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4.2 GlaxoSmithKline in time 
 - Every second, more than 30 doses of vaccines are distributed by GSK. 
 - Every minute, more than 1,100 prescriptions are written for GSK and every hour, GSK spends 
more than US $ 450,000 to find new products. 
 
 Every hour, GSK donates more than US $ 148 million in cash and products to communities 
around the world. 
4.3 History of GlaxoSmithKline 
 
Year History  
1873 The company was oriented as Joseph Nathan & Company in New Zealand with the 
founding of a small import export company. It started its operation as a processing 
unit of abundant fresh milk of New Zealand. The only product it was producing was 
Glaxo Baby Food. 
1875 It started to export baby food to UK Alec Nathan, son of Joseph Nathan, coined the 
name Glaxo from Glactose. 
1924 Joseph Nathan & Company entered the pharmaceutical industry with the manufacture 
of Ostelin, the first Vitamin D preparation. The importance of the pharmaceutical 
market was soon realized 
1935 Glaxo Laboratories Limited was founded with its headquarters at Greenford, 
Middlesex and London for the production and marketing of foods and 
pharmaceuticals. 
1947 After the 2nd world war, Glaxo developed rapidly. Glaxo Laboratories Limited 
absorbed its parent Joseph Nathan & Company, and became a public company. 
1963 Edinburgh Pharmaceutical Industries Limited, which owned Duncan, Flock hart and 
Company Limited and MAC Far lane Smith Limited, joined Glaxo. 
1995 Glaxo acquired 100% share, of Wellcome PLC on may 01, 1995 and formed Glaxo 
Welcome PLC. 
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1998 Glaxo Wellcome achieved a number of regulatory milestones for several of its key 
projects, such as ZEFFIX for the treatment of influenza. 
2000 Glaxo Weilcome and SmithKline Beecham merged to form GlaxoSmithKline; a 
worldwide research based pharmaceutical company. 
 
 
 
 
 
 
 
 
 
 
 
                                              Figure -1: Merging History of GSK  
4.4 GlaxoSmithKline- Mission, Strategic Intent & Spirit 
4.4.1 Mission 
The mission statement of the business-“Our global quest is to improve the quality of human life by 
enabling people to do more, feel heifer and live longer” 
 
4.4.2 Strategic Intent 
Our strategic intent states of business goal — “We want to become the indisputable leader in our 
industry.” 
 
            SmithKline 
      SmithKline Becham ((1989) 
 
      Becham               
 
                       
 
   
 
       Glaxo Wellcome (1995) 
 
Burroughs 
Wellcome 
 
 
 
           Glaxo 
 
GlaxoSmithKline, 27th   December, 2000 
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4.4.3 Spirit: “Our company spirit describes how we need to behave if we are to achieve our goal” —We 
undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for. 
 
4.4.4 Vision 
Becoming the undisputed leader in the industry means conquering the challenges that will be face as an 
industry and as a global society. 
4.4.5 Quality Statement: Quality is at the heart of everything we do- from the discovery of the molecule 
through product development, manufacture, supply and sale- and vital to all the services that support our 
business performance. 
4.5 Global Operation 
The operation of the company splits into three geographical region- Europe, the USA and International 
and each of which has separate pharmaceutical and healthcare organizations. GSK pharmaceutical’s 
International regions divided into seven geographical areas. The complete division is shown below- 
 
 
 
 
 
 
 
 
  
  
 
                GSK World wide  
    Europe   USA   International Region 
       Canada 
         Chaina 
        Japan  
Latin America  
  Middle East 
Sub Sahara 
Africa  
Asia Pacific  
    Bangladesh 
      India  
Sri Lanka and 
Singapore  
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                                                             Figure 2: Workstation of GSK 
 
 
4.6 GlaxoSmithKline Bangladesh Limited 
 
With an enviable image and reputation for the past 6 decades GlaxoSmithKline (GSK) Bangladesh 
Limited running its operation as a subsidiary of GlaxoSmithKline plc- one of the worlds’s leading 
research-based pharmaceutical and healthcare companies. In 1949 the Company commenced its journey 
in Bangladesh with its’ corporate identity as Glaxo in Chittagong as an importer. In 1967, the company 
established its own manufacturing unit at Chittagong. The facility till date is considered as one of the 
Centre of Excellence in Global Manufacturing & Supply Network of the Group. The global corporate 
mergers and acquisitions have seen the evolution of the Company’s identity in the past 6 decades. In line 
with mergers and acquisitions the identity changed from Glaxo to Glaxo Wellcome Bangladesh Limited 
following the Burroughs Wellcome acquisition in 1995 and finally to GlaxoSmithKline Bangladesh 
Limited during 2002 after merger with SmithKline Beecham in December 2000. The mega merger of the 
Company enables it to deliver cuffing edge advancements in health care solutions. The relentless 
commitment, setting of standards of ethical standards and quality backed leading edge technology of the 
Company has built a strong relationship between the stakeholders and GSK Bangladesh. With the ever 
committed 701 numbers of personnel all over the country GSK Bangladesh, which now comprises of both 
Pharma and Consumer, continually strive to meet the GlaxoSmithKline mission. 
 
4.6.1 Operations in Bangladesh Headquarter 
 
GlaxoSmithKline Bangladesh Limited 
Corporate Office 
House # 2A, Road # 138.  
Registered Office & Factory 
Fouzderhat Industrial Area 
North Kattali, Chittagong. 
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Gulshan-l. District Marketing Office  
 
 
GlaxoSmithKline Bangladesh Limited has twelve districts Marketing Offices (DM0) throughout the 
country. These are divided in five zones by which GSK’s products are sold. 
 
● District Marketing Offices: GSK has 12 District Marketing Offices (DM0) in Bangladesh. The 
locations of DMOs are shown below-  
 
Zone DMO 
Dhaka Dhaka, Mymensing 
Chittagong Chittagong, Maijdee 
Comilla Comilla, Sylhet 
Bogra Bogra, Rajshahi, Rangpur 
Khulna Khulna, Jessore 
Barisal Barisal 
 
Table: List of DMOs 
*Source: Secondary data, provided by Marketing Department 
4.6.2 GlaxoSmithKline Bangladesh Ltd. (In Market Place) 
• Total Market Share: TK. 140 Corers (2012) 
• Market Share: 1.95 % (2012) 
• Ranking: 12 (2012) 
4.6.3 Share Information GlaxoSmithKline Bangladesh Ltd. 
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•        Share Price Tk. 10 each and total No. of Authorized Share 20,000,000 
•  Authorized Share Capital Tk. 20,000,000 
•  Market Capitalization 6920.685 (Million) 
4.6.4 Distribution Channel 
•  Mutual Food- Distributor of consumer health care product of GSK, Bangladesh. 
•  Zuellig Pharma- Distributor of pharmaceuticals product of GSK, Bangladesh. 
4.7 Organizational structure of Company 
4.7.1 Top Management: 
As per provisions of the Article of Association, Board of Directors holds periodic meetings to resolve 
issue of policies and strategies, recording minutes/decisions for implementation by the Executive 
Management. 
4.7.2 Executive Management: 
The Managing Director heads the Executive Management, the Chief Executive Officer (CEO) who has 
been delegated necessary and adequate authority by the Board of Directors. The Executive Management 
operates through further delegations of authority at every echelon of the line management. 
4.7.3 Corporate Governance Structure: 
 
 
 
 
 
                                               Figure 3: GSK corporate governance Structure 
 
 
Corporate Governance 
Strategy 
Board of Directors Executive 
Committee 
Audit Committee 
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4.8 Functional department of GlaxoSmithKline Bangladesh Ltd. 
 
GlaxoSmithKline, Bangladesh, Limited comprises of five major departments. They are given below- 
• Human Resources 
• Marketing 
• Finance 
• Medical and regulatory affairs 
• Information Technology 
 
 
4.9 Products of GSK Bangladesh LTD: 
GSK is committed to develop new and effective heath care solutions. The values on which the group was 
founded have always inspired growth and will continue to do in times to come. In Bangladesh GSK is 
providing both Pharmaceutical and consumer Heath care products for its consumers.  
GSK works in the two broad areas of products markets: 
1. Pharmaceutical :   prescriptions, medicine and vaccines 
2. Consumer Healthcare: Over the counter medicines, Oral care and nutritional healthcare products. 
Product overview: 
1. Pharmaceuticals: 
GSK’s board pharmaceuticals product line includes antibiotic, antidepressant, gastrointestinal, 
dermatological, respiration, cancer and cardiovascular medications. GSK has a variety of vaccine 
products, including hepatitis A and B, diphtheria, tetanus, whooping cough and influenza. 
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2. Consumer Healthcare: 
GSK Consumer Health brings oral health care, over the counter medicines and nutritional health 
care products to millions of people. 
 
GlaxoSmithKline Products Glossary 
Local production  60 products including 
Berm 
Cytamen 
Kefdrin 
Pentamox 
Imported product 
  
17 products including 
Alkeran 
Seretide 
Zinnat 
Vaccines 17 products including 
Engerix-B 
Fluarix 
Synflorix 
Consumer Healthcare 9 products including 
Horlicks 
Chocolate Horlicks 
Junior horlicks 
Mother Horlicks 
Horlicks Lite 
Boost 
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Maltova 
Glaxose 
 
 
 
GSK’S Market Share & Position 
 
Year Market Share Position 
2007 2.90% 12 
2008 2.91% 12 
2009 2.24% 12 
2010 1.95% 12 
2011 1.95% 12 
2012 1.95% 12 
 
 GSK’s Market Share & Position (2007-2012) 
 
4.10 GSK’S Market Share & Position Comparison 
 
 
4.10 GSK’S Market Share & Position Comparison 
SQUARE 19.18% 1 
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INCEPTA PHARMA 9.05% 2 
BEXIMCO 8.62% 3 
OPSONIN PHARMA 4.94% 4 
ESKAYEF 4.84% 5 
RENATA 4.73% 6 
ACME 4.44% 7 
A.C.I. 4.08% 8 
ARISTOPHARMA 3.99% 9 
DRUG INTERNATIONAL 3.75% 10 
SANOFI AVENTIS 2.57% 11 
GLAXOSMITHKLINE 1.95% 12 
 
4.11 SWOT Analysis 
SWOT is the acronym for Strengths, Weaknesses, Opportunities and Threats. It is an analytical 
framework to help summarize in a quick and concise way the risk and opportunities for any company 
across the value chain. A good SWOT should look into internal and external factors affecting the issue at 
hand. 
- Factors pertaining to the internal environment of the company. These are usually classified as 
Strengths (S) or Weaknesses (W) 
- Factors that pertaining to the external environment of the company. These are classified as 
Opportunities (0) or Threats (T). 
 
Strength Weakness 
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• GSK is considered as world’s one of the leading 
pharmaceutical companies because of its 
performance. 
• Efficient, capable and honest workforce 
• GSK has intense demand of their 
product nationally and internationally which 
helps them to inflate their business 
• Considerable financial resources to 
grow the business 
• Proprietary technology and importance 
patents 
• Ability to take advantage of economies 
of scale 
• Better product quality relative to rivals 
• Goodwill of the company 
• Follows GMR-Good Manufacturing 
Practice 
• Underutilized plant capacity  
• Higher unit cost relative to competitors 
• Group compliance due to group policy the 
company has to import raw materials form UK 
rather from neighbor countries (other than those 
which are produces locally) resulting in higher 
cost of production. 
• Lack of variety in products 
• Low pack size 
• Lack of sufficient promotional effort. 
• GSK has weaker distribution network and sales 
force are relatively low compare to competitors. 
 
Opportunities Threats 
• GSK as a multinational company as 
Opportunity for expands its investment and has 
potential growth in Bangladeshi market. 
• Expanding the company’s product line to meet a 
broader range of customer reeds. 
• Target and acquire an untapped marketing for 
• Adverse shifts in foreign exchange rates and 
trade policies of government Aggressive 
movement of rivals Slow down in market growth 
Growing bargaining power of the end consumers, 
thus high priced medicine are inconvenient for 
them 
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vaccines 
• Market is significantly large and growing 
• Proper utilization of vaccines may result in 
higher profit. 
• Availability of natural resources is the most 
lucrative opportunity for GSK to work with 
Bangladesh. 
• In Bangladesh, GSK can get labors at a very 
cheap cost. 
• High confidence brand name and quality 
• Costly new regulatory requirements 
• Competitors lower prices 
• Increasing threats from local competitors. 
 
 
Chapter 5: GSK Bangladesh- Inventory Management Overview: 
This segment of the study, exploring the inventory management practice of GSK, is formulated based on 
the questionnaire response or primary data source. The responses of the three interviewees were almost 
similar. However, the summary of the interviewees’ responses regarding the inventory management and 
its effect on financial performances of the pharmaceutical segment of GSK is given below: 
The GSK, in spite of its tiny market share in pharmaceutical sector of Bangladesh, is determined to 
uphold product quality excellence and manufacturing efficiency. Manufacturing process improvement, as 
well as cost reduction through addressing lean technique is part of their continuous process improvement, 
material requirement planning is considered for managing inventory. Inventory records are maintained 
both manually and digitally. The company keeps records for each item. Weekly comprehensive stock 
counting is administered compared to the records to update the inventory situation and prevent theft and 
damage. 
The respondents revealed that the inventory management system used by GSK pharma is not adoptive to 
the current market scenario. The record, forecasting and material requirement planning software is up to 
date with modem technology but unfortunately not enough strong and efficient in perspective of 
Bangladesh. In most of the cases, the operation policies of GSK are prescribed by the parent organization, 
instead of analyzing the current market scenario and competitors activities. These practices lead GSK to 
become an isolated market player with huge potential but diminishing profitability. 
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Due to the complex nature of the “value stream” existing in the pharmaceutical industry, the company 
cannot contribute value directly to its end-users. However, it attentively manages its flow of products 
from supplier to primary sales point Zueillig Pharma Distributions Limited (ZPL) and closely monitors 
the distribution and secondary sale to accumulate the demand scenario in its business development, 
especially in production planning decision-making readily GSK’s J.D. Edwards ERP system which is 
managed and monitored by a team of efficient people, ensures cost efficiency in production by warning 
the production control unit regarding over production, inefficient transportation, waiting time, 
inappropriate processing, unnecessary stock, unnecessary motion, and rejects and defects. 
 
Inventory status report, containing current stock and requirement of raw material, packing materials, spare 
parts and other inventories, is regularly updated by the facility and recorded by both corporate and 
facility’s AIS (Accounting Information System). Based on the inventory status and production target 
purchase order is processed to the local, and foreign suppliers. After receiving the ordered materials, 
invoices and receipt notes are prepared. Accounts receivables are paid to the suppliers via checks or 
electronic fund transfers. Excise duties are recorded by the facility; on the other hand, VAT is deducted 
by the corporate Finance and Accounting Department while paying the bills by the suppliers. 
 
5.1 Key substances of Inventory Management of GSK BD Ltd. 
Like all other assets, inventory represents a costly investment to the firm. In order for this investment to 
be worthwhile there must be some advantage in making it. Those reasons vary with the type of inventory 
carried. For purpose of discussion I will use the accountant’s convention of dividing inventory into three 
types:  
Raw Material Inventory: 
 Having an available stock of raw materials inventory make production schedule easier. 
 To keep raw materials inventory is to avoid price changes. 
 Keep extra raw materials inventory to hedge against supply shortages.  
 Work- In- Process Inventory: 
Keep work-in-process inventory beyond minimum level to Buffer production  
Finished goods Inventory: 
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 Keep finished goods inventory to provide immediate service. 
 Keep finished goods inventory to Stabilize production. 
5.2 Purposes of Inventory management of GSK BD Ltd. 
The firms keep a supply of inventory for the following reasons are: 
 To maintain independence of operations. 
 To meet variation in product demand. 
 To allow flexibility in production scheduling. 
 To provide a safeguard for variation in raw material delivery time. 
 To take advantage of economic purchase-order size. 
5.3 Key Functions of inventory management systems of the GlaxoSmithKline Bangladesh Limited: 
The key functions of the GlaxoSmithKline Bangladesh Limited (GSK) inventory management 
systems are like 
 To ensure material is available. 
 Receipts, custody, and issue of materials. 
 To recording the record of all stock movements. 
 Co-ordinate with management, maintenance, production, marketing & finance departments and 
other departments in the company for meeting their requirements for materials and spares. 
 Assist in devising management reports.  
5.4 Types of Inventory of GSK BD Ltd. 
There are various types of inventory. Some of them are given below, Such as: 
  Work in Process. 
 Packing Materials. 
 Laboratory & Promotional Materials. 
 Physician Sample. 
 Raw & Packing Materials in Transit. 
 Stock of Stationery. 
 Spares & accessories and finished goods  
Raw Materials: The raw-materials inventory contains items that are purchased by the firm from others 
and are converted into finished goods through the manufacturing (Production) process. They are 
important input of the final product. 
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Work-in-Process: 
The Work-in-Process inventory consists of items currently being used in the production process. They are 
normally partially or semi-finished goods that are at various stages of production of multi-stage 
production process. 
Finished Goods: 
Finished goods represent final or completed products, which are available for sale. The inventory of such 
goods consists of items that have been produced but are yet to be sold. 
Packing Materials: 
The packing materials inventory contains of material packing related goods, which things are used for the 
purpose of packing materials. Mainly packing materials used for the purpose of cover the final products 
or to give it an attractive look. 
Laboratory & Promotional Materials: 
Laboratory and promotional material refers that which goods or materials are used for the purpose of 
laboratory and promotional activities. Usually this type of material used inside of the organization. 
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                             Figure 4: Flow of manufacturing and facility information 
Product quantity, which is the average of latest 3 months’ sale, is ordered by the primary customer ZPL. 
Besides, GSK processes shipment of pharmaceutical finished goods to other country organizations as per 
ordered by the global organization. Both accounts payables, accounts receivables and labor costs or 
employee payroll are recorded in the general ledger, which accordingly affects the company budget. 
All of the respondents identified high COGS as reasons one of the behind the diminishing revenue and 
GPM. GSK focuses immensely on the quality of raw materials and machine equipment. Most of these 
two categories are imported, which is a major reason behind high shipping and ordering cost, as well as 
high inventory value. 
 
 
Chapter 6:  Financial Performance overview of GSK BD Ltd 
(Financial Performance of the company) 
6.1 Net profit Margin (NPM): It is an important measure of the profitability of a venture after 
accounting for all costs. In a survey of nearly 200 senior marketing managers 91% responded that they 
found the “Net Profit” metric very useful (Wikipedia, 2013) 
 
 
                                                  Figure 5: Net profit margin of GSK 
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This ratio of profitability is calculated as net profit divided by sales. It measures how much out of every 
BDT of sales a company actually keeps in earning. According to the graph, on the financial year 2010 the 
NPM was the highest, about 14%. The statistics of financial year 2011 and 2012 indicates a diminishing 
trend in NPM. The company had a net income of BDT 8 and 5 for each BDT 100 of sales respectively for 
the years 2011 and 2012.  
Interpretation: 
The company has costs that have increased at a greater rate than sales, which leads to a lower profit 
margin. This is an indication that costs need to be under better control. This low profit margin trend can 
also indicate that the pricing strategy and/or the impact competition are on margins. 
6.2 Cost of Goods Sold (COGS) to Operating Profit (OP) Ratio 
COGS refer to the inventory costs of the goods a business has sold during a particular period. It is a very 
important component of inventory management. COGS is consisted of material, labor, and allocated 
overhead costs. The following ratio expresses the percentage of GP earned against investment as COGS. 
This ratio was calculated dividing OP by COGS. 
Operating profit (OP) or earnings before interest and tax (EBIT) is a significant financial performance 
indicator. It is calculated as, OP = Revenue - COGS- Operating Expenses - Depreciation & Amortization. 
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                                          Figure- 6: COGS to operating profit Ratio of GSK 
According to the analysis, the Company is experiencing an increasing trend in earning operating profit 
against COGS investment. For each BDT 100 investment as COGS, the company has earned BDT 21, 22, 
27 and 31 respectively for the financial years 2009, 2010, 2011, and 2012. 
 
Interpretation: 
Despite of having increasing COGS the increasing trend of OP statistics and COGS to OP ratio is 
showing an optimistic view. 
6.3 Gross Profit Margin (GPM) 
GPM, expressed in percentage, is a financial metric used to assess a firm’s financial health by revealing 
the proportion of money left over from revenues after accounting for the cost of goods sold. Gross profit 
margin serves as the source for paying additional expenses and future savings. It is calculated as: 
(Revenue - COGS)/Revenue. (Investopedia, 2013) 
 
                                     Figure 7: Gross profit Margin of GSK 
As par the graph, comparing against the margins of previous years, the pharmaceutical segment of GSK is 
experiencing a decreasing trend in GPM in recent two years. The margin decreased from 34.2% in year 
2010 to 28.5% in year 2011. After this decline, it experienced a slight increase of 0.1% in year 2012. 
Interpretation 
The increasing trend of GPM for the year 2010 gives a good indication of financial health of the segment. 
Lower profit margins do not indicate efficiency. Based on the analysis, it can be said that without an 
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adequate gross margin, the company will be unable to pay its operating and other expenses and improve 
investment capacity for the future. 
6.4Current ratio to Quick Ratio Comparison 
Quick ratio and current ratio can provide the liquidity position or financial stability of an organization. 
While QR veers toward the more conservative side of the spectrum, CR tends to be more liberal in its 
conclusion of a company’s hinds. The difference between these two ratios is QR discounts inventory as 
an asset that is not readily available, CR includes it. 
 
                             Figure 8: Current ratio to Quick Ratio comparison 
According to the study, all of the QR numbers are above 1.00. CR for year 2009, 3.11, was much higher 
than any other years’. Besides, the QR numbers have also decreased significantly over years. The CR to 
QR ratio indicates that the decline in QR is sharper than CR until year 2012. CR to QR ratio of year 2012 
was improved to 1.05 from 1.2 of year 2009. 
Interpretation 
All of the QR numbers are above 1.0, indicating the company is almost certainly financially secure. 
Decrease in QR indicates the decrease in cash or accounts receivable balances, without a corresponding 
decrease in current liabilities, or increase in a current liability without a corresponding increase in cash or 
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accounts receivables. CR decreases as any current asset decreases, without a corresponding decrease in a 
current liability, or if a current liability increases without a corresponding increase in a current asset. 
 
 
6.5 ROE and ROA 
Both ROE and ROA Judge a company’s ability to generate earnings from its investments as well as 
provide a clearer representation of a company’s performance. ROE shows how effectively a company’s 
management is using investors’ money and is growing the company’s value at an acceptable rate. ROA 
reveals how much profit a company earns for every dollar of its assets. The big factor that separates ROE 
and ROA is financial advantage, or debt. However, if that company takes on financial advantage, ROE 
would rise above ROA. If ROA is sound and debt levels are reasonable, a strong ROE is a solid signal 
that managers are doing a good job of generating returns from shareholders’ investments. 
 
                                            Figure 9: ROE and ROA of GSK 
A decreasing trend of ROE of 29%, 20%, and 17% respectively for the years 2010, 2011, and 2012 
indicates the company management is being less efficient in returning to its shareholders’ investments. 
Additionally, the ROA is also declining, which indicates the company is performing low in making profit 
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against each taka of assets. 24%, 18%, 12% and 11% are the respective ROA for the years 2009, 2010, 
2011, and 2012. 
Interpretation 
Decreasing ROE trend is certainly a “hint” that management is being less successful to provide 
shareholders return that is more attractive for their money. On the other hand, declining ROA indicates 
the company has started carrying increasing amount of debt, winning the strength of its asset base or has a 
waning tendency in net income. 
6.6 Comparative Inventory Related Financial Performance within the Pharmaceutical Industry: 
This section of the study focuses on analyzing the competitor organizations’ financial and inventory 
related performance. Square, Beximco and Renata Pharmaceutical’s historical financial data for the years 
2010, 2011, and 2012 was analyzed. 
 6.6.1 Net Sales 
Net sales is the amount of sales generated by a company after the deduction of returns, allowances for 
damaged or missing goods and any discounts allowed. The sales number reported on a company’s 
financial statements is a net sales number, reflecting these deductions. 
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Figure-10: Comparison of Net sales with Industry Average 
According to the graph, Square is clearly dominating the market in terms of net sales for years. Beximco 
has possessed a sound and positive growth trend in sales. Both Renata and GSK are performing 
significantly lower than the first two manufacturers, as well as the industry average. For year 2012, GSK 
could earn about 6 billion BDT as net sales, while the industry average was about 9 billion BDT and 
Square earned 16 billion BDT. 
6.6.2 Average Inventory: 
Average inventory is the median value of an inventory throughout a certain period. This study considered 
the average of opening and closing inventory for a year as the average annual inventory value for that 
year
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                             Figure 11: Comparison of Average Inventory with industry Average 
As par the analysis, the average inventory of GSK for the years 2010 and 2010 were significantly higher 
than the industry average and any other of the three competitors, which is rather inefficient as the unsold 
inventory may become obsolete and results higher carrying cost. On year 2012 the average inventory of 
GSK decreased from 4046 million BDT to 1635 million BDT, which is below industry avenge of 2013 
million BDT. The statistics of average inventory for the other pharma companies are relatively stable than 
that of GSK’s. 
Gross Profit Margin Analysis 
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                            Figure- 12: Gross Profit Margin in Industry context.  
The above figures state that the COGS of GSK had increased from year 2010 (2390 million BDT) to 
2011(3965 million BDT) but in proportion to that, the gross profit did not increase. As a result, the GPM 
decreased significantly indicating that the pharma segment of the company becoming Less profitable. In 
contrast to that on year 2012 the GPM increased as the COGS decreased as well as the GP remained 
almost unchanged. 
 
Quarterly Inventory Statement 2010- 2012 (For pharmaceutical segment) 
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Figure 13: Inventory Summary for Year 2010, 2011, 2013 
The analysis of the inventory statements for the year 2010 to 2012 reveals that finished goods occupy the 
major part of the inventory. FG consisted 31%, 33% and 39% of the total annual inventory for the 
respective years. Commercial and GMS inventory are second and third major inventory for respective 
years. Commercial and GMS inventory are second and third major inventory items in terms of monetary 
values. In contrast, raw materials, packing materials and work- in process inventory consists insignificant 
portion of the inventory. The chart below shows that, GSK’s total inventory value had increased over year 
from 2010 to 2011.  
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                                  Figure 14: Inventory Growth Trend  
Large amount of finished goods results into high carrying and maintaining cost, which is not an indication 
of inventory management efficiency. Besides, higher commercial and GMS inventory indicates the 
company is spending huge amount of money in importing inventory. As a result, the COGS are becoming 
higher.  
6.7 Economic Order Quantity Analysis: 
The EOQ model considers the tradeoff between ordering cost and storage cost in choosing the quantity to 
use in replenishing item inventories. This cost minimizing order-quantity called EOQ, is the order point at 
which total cost and order cost is minimum than other ordering quantity (Schwarz, 2008) 
Followings are assumption for calculating EOQ: 
Relatively uniform & known demand rate 
Fixed item cost  
Fixed ordering and holding cost  
Constant lead time Annual sales unit = annual inventory units ( Ferderick S Hiller, 2010)  
This study calculated the annual EOQ s for years 2010, 2011 and 2013 by using this formula 
EOQ = √[( 2*D*K) / (H *P)]  
Here, K= Ordering cost per order 
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D= Annual demand of inventory (raw materials and packing material) in units  
H= Holding carrying costs expresses as a percentage of inventory value  
P= Purchase price the firm must pay per unit of inventory  
Ordering period (Practicing) = 2 weeks  
Assumption was made that, annual/quarterly finished goods amount is the total amount desired to be sold. 
As no interest rate is paid for COGS ( fully equity financed),current average FDR rate practice by the 
commercial banks ( 11.395) was considered and calculated as the opportunity cost, ( Bangladesh Bank, 
2013) Annual carrying cost 18.39% on inventory value was calculated based on the cost information 
provided by GSK . Average selling price per unit for years 2010, 2011 and 2012 were respectively BDT 
140,175 and 110 as par the information provided by GSK: 
Description  Year 2010  Year 2011 Year 2012 
Cost per order  4,856,847.15 4,250,019.54 5,463,674.75 
Annual Demand 114,194 164,562 155,532 
Value of inventory per 
unit  
2,570 3,257 2,993 
Inventory Carrying cost 
rate  
.31% .27% .29% 
Number of units 
produced per batch 
5,000 5,000 5,000 
Cost of carrying 
inventory  
2,022,901.61 2,183,808.31 2,160,829.73 
Cost of orders 110,924,560.59 139,878,343.16 169,955,252.24 
Total Inventory carrying 
cost& Setups 
112,947,462.20 142,062,151.47 172,116,081,97 
EOQ 37,025 40,016 44,343 
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Times of orders 
required  
3 4 4 
                                                          Annual EOQ calculation 
The excel calculation of EOQ reveals , 37025, 40016 and 44343 units were respectively the cost 
minimizing order quantity for the years 2010,2011 and 2012. Highest cost per order, total cost of orders, 
total cost of inventory carrying and setups and EOQ was experienced on year 2012. In contrast to that, 
annual demand and per unit inventory value were seen on year 2011. Inventory carrying cost rate was 
highest on year 2010. 
The growth in EOQ over years seems relatively stable. However, times of inventory required calculated 
by the study for the year 2010 (3 times) is longer which may indicate inventory damage or obsolete rate.  
 
                                       Figure 15: Sales and Calculated EOQ 
 
 
.  
Analysis revealed for year 2012 units of sales raised significantly, while EOQ declined sharply as well. 
On the other hand, year 2011 experienced as increased EOQ along with decreased annual net sales. This 
indicated no straight interrelationship between EOQ and annual net sales. Large order-quantity reduced 
ordering frequency, and hence ordering cost month, but requires holding a larger average inventory, 
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which increases storage cost month. On the other hand, a smaller order- quantity reduces average 
inventory but requires more frequent ordering and higher ordering cost/month. 
 
6.7.1 Inventory Turnover Rate Calculation for Pharma (Annual Average): 
ITR is a ratio showing how many times a company’s inventory is hold and replaced over a period. The 
days in the period can be divided by the inventory can then be divided by the inventory turnover formula 
to calculate the days it takes to sell the inventory on hand or “Inventory turnover days”. 
The average inventory for this study was calculated: 
(Beginning inventory + Ending inventory)/2 
Average inventory accounts for any seasonality effects on the ratio. A low turnover, in comparison to 
industry averages implies poor sales and therefore, excess inventory. A high ratio implies either strong 
sales or inefficient buying. High inventory levels are unhealthy because they represent an investment with 
a rate of return of Zero. It also opens the company up to trouble should prices begin to fall. ( Investopedia, 
2013). 
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                                             Figure 17: ITR on sales and cost 
According to the analysis, GSK’s ITR on sales is significantly lower than the calculated ITR. 
Additionally, this company’s ITR on cost also lower than the industry ITR. GSK experienced 0.49 ITR on 
sales which is significantly lower than 2011’s ITR 1.17, as well as, 2012’s industry ITR 3.33.  
 
                                               Figure 18: Comparison of IT Days with Industry 
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Study calculated IT days using the formula: 
ITD = Number of Days in a period/ITR 
According to the analysis, the IT days had been significantly lower for all the three years than the industry 
average IT days. 162 days, the IT s=days for sales for year 2012 was much lower than the previous year’s 
IT days 329, as well as, year 2012’s industry average 277 days. 
Interpretation  
Decreasing inventory turns reduces holding cost. The organization spends more money on rent, utilities, 
insurance, theft and other costs of maintaining a stock of good to be sold.  
 
                                     Figure – 19: Comparison of Actual and Ideal Inventory Values 
Ideal inventory value IIV) was calculated by using the formula: 
IIV = Annual COGS/ Industry Average ITR 
Analysis indicates actual IV of GSK was relatively in more coordination with the calculated IIV on costs 
than the IIV on sales. The IIV on sales had been relatively constant over years and were much lower than 
both the actual TV and cost-based IIV. For the year 2012, the actual IV 52525457 BDT (‘000) was higher 
than the IIV on both costs and sales. 
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Interpretation: 
GSK is consistently experiencing low turnover, which is usually a bad sign because products tend to 
deteriorate as they sit in a warehouse.  
GSK’s high average days of inventory indicates that the company is not properly managing its inventory 
or that it has a substantial amount of goods, which are proving difficult to sell. The higher a firm’s 
average age of inventory, the greater its exposure to obsolescence risk, the risk that the accumulated 
products will lose value in a soft market.  
 
 
Chapter 7: Findings, Recommendation and Conclusion 
Findings: 
Financial performance of GSK is much lower than the other market performances’. Besides, the historical 
performance of the company is at wane.  
1. The company’s gross profit margin is not stable. Trend of decreasing sales accompanied by 
increasing COGS is resulting into diminishing revenue, GPM, ROA and ROE.  
2. From the perspective of liquidity ratios analysis it can be stated, the company is almost certainly 
financially secure.  
3. This study revealed that GSK is remaining at a meager position in Pharmacy manufacturing 
industry in terms of average inventory maintenance and GPM. Lowest average inventory value 
may indicate minimum total inventory costs, but the least ability of the company in meeting the 
market demand.  
4. Quarterly Inventory statements analysis for three years revealed the majority of finished goods 
over the other inventory components, resulting high carrying and maintaining cost. Additionally, 
an increasing trend in total inventory value had been observed which indicates company’s 
dependency on costly imported inventory. 
5.  GSK’s ITR on both sales and cost is significantly lower than the industry average, which implies 
poor sales and therefore, excess inventory. However, this low ITR provides the company 
protection against trouble resulted from unexpected fall ion price of product.  
6. Currently the company is managing it a manufacturing operation based on the historical sales 
data. The total manufacturing cost, specially ordering and holding costs could be significantly 
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less if the company addressed standard operation cost minimizing integrated inventory 
management system, such as EOQ.  
 
Recommendation: 
The company should identify and access less costly local or foreign source of inventory for their 
Pharma products to reduce the COGS as well as to acquire strong profit position in the industry. 
The percent company should consider the pharmaceutical market of Bangladesh as a potential 
one. It should concentrate on formulating and exercising competitive strategies to regain its lost 
dominating position in the market.  
 
Conclusion:  
This study on “Inventory management and Financial Performance of the Pharmaceutical segment 
of GSK Bangladesh Limited” shows the overall scenario of GSK’s pharmaceutical segment 
performance in Bangladesh. In addition, it also describes the effect of Inventory management on 
the financial performance of GSK Bangladesh LTD.  Moreover, this study illustrates the 
comparison among few competitors of GSK in perspective of financial performance. Finally, it 
reminds the management of GSK of the need to streamline local inventory management 
procedures and strategies effectively to boost the levels of financial performance.  
 
The parent company, with is age reputation in manufacturing quality goods and operation 
excellence in this country should consider the pharmaceutical market of Bangladesh as a potential 
one. It would be wise for GSK to concentrate on formulating and exercising competitive business 
strategy such as addressing efficient inventory management procedure to regain its market 
position.  
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 EOQ Information Schedule 
 
Economic Order Quantity Analysis (EOQ) 
  S F P C EOQ 
(cal) 
Period Quarter Total 
Desired to 
Sell 
Shipping 
Costs 
Purchasing 
Costs 
Interest 
Rates 
Calculated 
EOQ 
Year-1 1      
 2      
 3      
 4      
Annual       
Year-2 1      
 2      
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 3      
 4      
Annual       
Year-3 1      
 2      
 3      
 4      
Annual       
Inventory Turnover Rata Statistics 
Period Annual (COGS (Avg.) Retail Sales (Avg.) Sales in Units (Avg.) 
Year-1    
Year-2    
Year-3    
Average Inventory (AI) Statistics  
Period AI at Cost AI at Retail AI in Units 
Year-1    
Year-2    
Year-3    
Inventory: Basic Statistics  
Description -> Year    
Raw Materials     
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Packing Materials     
Work in Process     
Finished Goods    
Stores & Spares    
GMS    
Commercial     
Total Inventory Value (in thousands)    
Total Inventory Value (in million BDT)    
  
Number of Days in a Period:   Lead-time:  
Inventory Turnover Rate:   Any seasonal trend: YES/NO 
Industry Average Turnover Rate:  
 Important Excel Calculations:  
 
GSK’s Financial Performance Analysis (The Company) 
Financial Performacne     
Year Sales COGS  Operating Net Profit COGS to 
OP 
2009 3023672000 2079389000 944283000 431859000 323787000 0.208 
2010 3632095000 2389742000 1242353000 535597000 410177000 0.224 
2011 4735121000 3386670000 1348451000 907013000 282068000 0.268 
2012 5553812000 3964900000 1588912000 1213242000 243967000 0.306 
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Operating Performance  Profitability  EO Liquidity 
Year TGR GPM OPM NPM ROE ROA CR QR CR/O
R 
2009  0.310 2.03 0.11 0.278 0.243 3.11 2.54 1.2 
2010 1.202795274 0.342 1.24 0.14 0.297 0.185 2.59 2.16 1.2 
2011 1.253852928 0.285 1.69 0.08 0.204 0.127 1.89 0.96 2.0 
2012 1.233554719 0.286 1.34 0.05 0.177 0.110 1.79 1.05 1.7 
 
Notes:  
Turnover growth rate= TGR Turnover (current)/Turnover (Previous) 
Gross profit ratio=GPR   
Operating profit margin  Operating Profit (current)/Operating Profit (Previous) 
Net Profit margin   Net Profit/Sales 
Inventory turnover  COGS/Annual Inventory  
Current ratio 
Quick ratio   Quick Ratio=(Current Asset-Inventories)/Current Liability  
OE Operating Efficiency  
 
Comparative Inventory Related Financial Performance within the Industry  
 2010 
 Square Beximco Renata GSK 
50 | P a g e  
 
Net Sales 11462578410 6490847353 3900732314 3632095000 
Opening Inventory 2098755231 1722953284 959414590 610525000 
Closing Inventory 2207078082 1983809444 1075310581 6952310000 
Average Inventory  2152916657 1853381364 1017362586 3781417500 
Cost of Goods 
Sold 
6561288485 3317640254 1820496777 2389742000 
Gross Profit 4901289925 3173207099 2080235537 1242353000 
     
ITR on Cost 0.33 0.56 0.56 0.63 
ITR on Sales 5.32 3.50 3.83 0.96 
Gross Profit 
Margin 
0.75 0.96 1.14 0.52 
 
 2011 
 Square Beximco Renata GSK 
Net Sales 13471424469 7890241843 5090318113 4735121000 
Opening Inventory 2207078082 1983809444 1075310581 6952310000 
Closing Inventory 2541688329 2291844631 1295855164 1138844000 
Average Inventory  2374383206 2137827038 1185582873 4045577000 
Cost of Goods 
Sold 
7703661010 4103709021 2405361976 3964900000 
Gross Profit 5767763459 3786532822 2684956137 1348451000 
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ITR on Cost 0.308214913 0.520949957 0.492891666 0.980057974 
ITR on Sales 5.673652188 3.690776524 4.293515225 1.170443919 
Gross Profit 
Margin 
0.748704214 0.922709871 1.116237873 0.340097102 
 
 
 
 2012 
 Square Beximco Renata GSK 
Net Sales 16054425243 9289115284 6519639234 5554000000 
Opening Inventory 2541688329 2291844631 1295855164 1138844000 
Closing Inventory 2687818472 2433987981 1585100179 2131740000 
Average Inventory  2614753401 2362916306 1440477672 1635292000 
Cost of Goods 
Sold 
9167253620 4899713857 3099355955 3386670000 
Gross Profit 688717623 4389401427 3420283279 1588912000 
     
ITR on Cost 0.285227526 0.48225598 0.464766775 2.070987934 
ITR on Sales 6.139938565 3.931207915 4.526025889 3.396335333 
Gross Profit 
Margin 
0.751279708 0.895848524 1.103546456 0.469166467 
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 Industry Average 
  2010 2011 2012 
Net Sales  6,371,536,269 7,796,776,356, 9,354,294,940 
Opening Inventory  1,347,912,026 3,054,627,027 1,817,058,031                                                                                                                                                                                               
Closing Inventory  3.054.627.027 1,817,058,031 2,209,661,658                                                                                                                                                                                                                                                                                                                                                                                                                    
Average Inventory                                                                      2,201,269,527 2,544,408,002 2,013,359,845                                                           
                                                                        
Cost of Goods 
Sold 
 3,522,291,879 4,544,408,002 5,138,248,358 
Gross Profit  2,849,271,390 3,396,925,855 4,071,442,082 
     
ITR on Cost  0.52 0.58 0.83 
ITR on Sales  3.41 3.71 4.50 
Gross Profit 
Margin 
 0.84 0.78 0.80 
 
Notes:  
COGS Cost of Goods Sold 
ITR Inventory Turnover Rate 
ITR on Cost Inventory/COGS 
ITR on Sales Sales/Average Inventory at 
Sales 
Gross Profit Margin COGS/Gross Profit 
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COGS (in Million BDT) 2,390 3,965 3,387 
GP (in Million BDT) 1,242 1,348 1,589 
 
 
Quarterly inventory statement 2010-2012  
Quarterly Inventory Statement 2010-2012 (for pharma) (BDT 000) 
 
Description Actual Current 2010 
Stock and Stores March June September December Total 
Raw Materials (RM)  89150 80616 67467 237233 
Packing Materials 44340 36838 37759 39481 158418 
Work-in-Process (WIP) 28286 38235 36960 35045 138526 
Finished Products-Local (FPL) 181109 189300 192358 195481 758248 
Finished Products-Local(FPL) 176542 198208 255982 189757 820489 
Store and Spares (S&S) 20329 19324 21131 20615 81399 
      
Total Stock and Stores 450606 571055 624806 547846 2194313 
      
Stock-in-Transit      
Raw Materials 14079 34909 26765 24010 99763 
Packing Materials 682 1265 4428 665 7040 
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Finished Goods (FG) 15995 13395 17130 17330 63850 
Spare Parts (SP) 0 720 0 4 724 
      
Total in Transits 30756 50289 48323 42009 171377 
 481362 621344 673129 589855 2365690 
Total Stock      
      
Actual      
GMS 225515 220441 207659 187287 840902 
Commercial 213646 260637 264770 250568 989621 
      
Total Actual 439161 481078 472429 437855 1830523 
Total Inventory 920523 1102422 1145558 1027710 4196213 
 
Description Actual Current 2011 
Stock and Stores March June September Decembe
r 
Total %Chan
ge 
Raw Materials (RM) 128639 121012 105702 98924 454277 0.91 
Packing Materials 37747 40178 49487 55404 182816 0.15 
Work-in-Process (WIP) 31466 40932 39724 55913 168035 0.21 
Finished Products-Local 
(FPL) 
135550 184869 89971 95526 505916 0.33 
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Finished Products-
Local(FPL) 
115285 238862 328253 387206 106960
6 
0.30 
Store and Spares (S&S) 21331 21428 23101 23004 88864 0.09 
       
Total Stock and Stores 470018 647281 636238 715977 246951
4 
0.13 
       
Stock-in-Transit       
Raw Materials 24853 47107 36224 28799 136983 0.77 
Packing Materials 1553 2592 848 2599 7592 0.08 
Finished Goods (FG) 4893 40201 42214 42834 130142 0.04 
Spare Parts (SP) 436 0 0 0 436 0.40 
       
Total in Transits 31735 89900 79286 74232 275153 0.61 
       
Total Stock 501753 737181 715524 790209 274466
7 
0.16 
       
Actual      0.24 
GMS 224602
5 
273249 255086 264643 103900
3 
0.42 
Commercial 213774 384024 390484 415658 140394
0 
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Total Actual 459799 657273 645570 680301 244294
3 
0.33 
Total Inventory 961552 139445
4 
1361094 1470510 518761
0 
0.4947573
6 
Description Actual Current 2012 
Stock and Stores March June September Decembe
r 
Total %Chan
ge 
Raw Materials (RM) 109929 127181 88337 70182 395629 0.13 
Packing Materials 58356 54913 73256 57615 244140 0.34 
Work-in-Process (WIP) 42674 48759 42351 47354 181138 0.08 
Finished Products-Local 
(FPL) 
78419 145356 131779 104228 459782 0.09 
Finished Products-
Local(FPL) 
269700 266228 312695 248353 109697
6 
0.03 
Store and Spares (S&S) 19972 22633 19592 21038 83235 0.06 
       
Total Stock and Stores 579050 665070 668010 548770 246090
00 
0.00 
       
Stock-in-Transit       
Raw Materials 47687 4146 21150 6673 79656 0.42 
Packing Materials 4269 923 4989 1396 11577 0.52 
Finished Goods (FG) 5931 33199 29756 8263 77149 0.41 
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Spare Parts (SP) 0 0 0 0 0 1.00 
       
Total in Transits 57887 38268 55895 16332 168382 -0.39 
       
Total Stock 636937 703338 723905 565102 262928
2 
-0.04 
       
Actual       
GMS 282887 258555 249675 204258 995375 -0.04 
Commercial 354050 444783 474230 35737 162780
0 
0.16 
       
Total Actual 636937 703338 723905 558995 262317
5 
0.07 
Total Inventory 127387
4 
140667
6 
1447810 1124097 525245
7 
0.031736
9 
       
Note: 
 1.  Since the inventory data for year 2009 was no available, inventory trend for year 2010                        
         could not be compared.  
 2.    GMS     Global Manufacturing & Supply  
 
 
 Summary Inventory Statement  
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Description 2010 2011 2012 
RM 336996 591260 475285 
PM 165458 190408 255717 
WIP 138526 168035 181138 
FG 1642587 1705664 1633907 
S&S 82123 89300 83235 
GMS 840902 1039003 925375 
COM 989621 1403940 1627800 
Total Inventory Value (in thousand) 4186213 5187610 5252457 
Total Inventory Value (in million 
BDT) 
4196 5188 5252 
 
Economic Order Quantity Analysis  
 
   D  K  C  h h/
c 
 
Peri
od 
Qu
arte
rs 
RM+P
M 
Deman
d 
(BDT) 
Inven
tor 
Dem
and 
(units
) 
Shippin
g (Qtr, 
in BDT) 
Per 
Order 
Cost 
(BDT) 
Purchasi
ng Cost 
(BDT) 
Ver
t 
Cos
ts 
unit 
(BD
T) 
Carryi
ng 
Cost 
(at 
18.39
%) 
C
C 
pe
r 
un
it 
(B
D
C
C 
as 
a 
% 
of 
C 
EOG 
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T) 
Yea
r-
201
0 
1   23,141,
083 
48568
47 
1900460
40 
     
 2   29,141,
083 
48568
47 
2092938
51 
    
 3   29,141,
083 
48568
47 
3655075
45 
    
 4   29,141,
083 
48568
47 
9834143
93 
   137085
9562 
Ann
ual 
 502,454
,000 
114,1
94 
116,564
,332 
48568
47 
1748,261
,828 
2,5
70 
92,401
,291 
80
9 
0.
31 
37025 
Yea
r-
201
0 
1   25,500,
117 
42500
20 
2608828
00 
     
 2   25,500,
117 
42500
20 
3717991
12 
    
 3   25,500,
117 
42500
20 
4154858
24 
    
 4   25,500,
117 
42500
20 
8538854
80 
   160131
2058 
Ann
ual 
 781,668
,000 
164,5
62 
102,000
,469 
42500
20 
1,902,05
3,216 
3,2
57 
143,74
8,745 
87
4 
0.
27 
40016 
Yea
r-
201
1   32,782,
049 
54636
75 
2192092
79 
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0 
 2   32,782,
049 
54636
75 
3467885
89 
    
 3   32,782,
049 
54636
75 
2155292
66 
    
 4   32,782,
049 
54636
75 
1812943
305 
   196631
19349 
Ann
ual 
 731,002
,000 
155,5
32 
131,128
,194 
54636
75 
2,594,47
0,439 
2,9
93 
134,43
1,268 
86
4 
0.
29 
44343 
            
 
 2010 2011 2012 
Demand (in ‘000 units 114 165 156 
EOQ 37,025 40,016 44,343 
EOQ value (BDT) 95,154,560 130,333,406 132,719,196 
EOQ (IV=X) Annual total 2,283,709,444 3,128,001,750 3,185,260,712 
Total Cost on EOQ 323,437,841 470,933,690 503,834,518 
 
Note: 
 Annual/quarterly finished goods is the total desired to sale. 
1. No interest rate is paid, fully equity financed.  
2. Calculate the opportunity cost only. Fdr rate can be the best suitable. You need the reference.  
S  Annual sales in units 
C Carrying Cost/Opportunity Cost. (Here, the current average of FDR is considered 
as the “C”/Opportunity Cost, as the operation is totally financed by equity).   
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FDR 11.39 
*** EOQ  0 ([(2*F*S)/(c*P)] 
 F  Ordering cost (placing and receiving an order) 
 S  Annual sales in units 
 C  Carrying costs expressed as a percentage of inventory value    0.1839 
 P  Purchase price the firm must pay per unit of inventory  
 
 3 Ordering Period  2 weeks  
 Assumptions:  
 Relatively uniform & known demand rate 
 Fixed item cost 
 Constant lead time 
Annual sales unit = annual inventory units  
4. Total cost c*D+k*d/Q+h*q/2 
 
 
 
EOQ Calculation Table 
    
Description Year 2010 Year 2011 Year 2012 
Cost per Order 4,856,847,15 4,250,019,54  
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Annual Demand 114,194.00 164,562.00  
Value of Inventory per unit 2,570.00 3,257.00  
Inventory Carrying Cost Rate 0.31 27% 0.29 
Number of Units per Batch 5,000.00 5,000.00 5,000.00 
    
Cost of Carrying inventory  2,022,901.61 2,183,808.31 2,160,829.73 
    
Cost of Order 110,924,560.59 139,878,343.16 169,955,252.24 
    
Total cost of inventory of carrying and 
set 
112,947,462.20 142,062,151.47 172,116,081.97 
    
Economic Order Quantity  37,025 40,016 44,343 
    
Times of orders required  3 4 4 
 
Inventory Turnover rate Calculation for Pharma (Annual Average) 
ITR bassed 
on Cost 
Annual 
COGS (BDT) 
Average Inventory 
at Cost (BDT) 
Turnover It Growth IA. 
Turnover 
Year-2010 2,389,742,000 3,781,417,500 0.63 - 0.52 
Year-2011 3,864,900.00 4,045,577,000 0.98 0.55 0.58 
Year-2012 3,386,670.00 1,635,292,000 2.07 1.11 0.83 
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ITR bassed 
on Sales 
Sales (BDT) Average Inventory 
at Sales (BDT) 
0.96   
Year-2010 3,632,095,000 3,781,417,500 1.17 0.22 3.41 
Year-2011 4,735,121,000 4,045,577,000 3.40 1.90 3.71 
Year-2012 5,554,000,000 1,635,292,000   4.50 
      
      
ITR bassed 
on Units of 
Merchandise 
Sales in units Average inventory 
in units 
   
Year-2010 114194 5753 24   
Year-2011 154562 6857 24   
Year-2012 155532 6481 24   
      
ITR bassed 
on Turnover 
Dayes 
Sales in 
Periods 
Average inventory 
Rate (Cost) 
   
Year-2010 335 0.63 212  175 
Year-2011 336 0.98 329  193 
Year-2012 336 2.07 162  277 
Notes: 
ITR based on Cost= Annual COGS/Average inventory at cost 
ITR based on Sales= Sales/ Average inventory at Sales 
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ITR based on Units of Merchandise= Sales in Units/Average inventory in units 
Inventory Turnover Days=Number of days in a Period/Inventory TurnoverIdeal Inventory Value= Annual 
COGS/ Industry Average Turnover Rate 
* All sales are primary sales, Compare with industry ITR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
